ARID4B and acute myeloid leukemia: Most patients with AML and ALL have a high level of BCAA transporters (BCAT1), while serum BCAA levels are reduced, suggesting active absorption of BCAA (Kikushige et al., 2023) and the formation of secondary metabolites (dipeptides).